ICIs targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) or its ligand (PD-L1) inhibit negative immune regulation, thereby enhancing anti-cancer immune activity. Here, CTLA4 is linked to cancer.